Fintel reports that on February 13, 2026, Oppenheimer upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Perform to Outperform.
Analyst Price Forecast Suggests 14.51% Upside
As of February 4, 2026, the average one-year price target for Vertex Pharmaceuticals is $532.50/share. The forecasts range from a low of $360.99 to a high of $656.25. The average price target represents an increase of 14.51% from its latest reported closing price of $465.02 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Vertex Pharmaceuticals is 10,721MM, a decrease of 10.67%. The projected annual non-GAAP EPS is 19.52.
What is the Fund Sentiment?
There are 2,463 funds or institutions reporting positions in Vertex Pharmaceuticals. This is an decrease of 214 owner(s) or 7.99% in the last quarter. Average portfolio weight of all funds dedicated to VRTX is 0.36%, an increase of 9.63%. Total shares owned by institutions decreased in the last three months by 8.10% to 281,598K shares. The put/call ratio of VRTX is 0.87, indicating a bullish outlook.
What are Other Shareholders Doing?
Capital World Investors holds 25,510K shares representing 10.05% ownership of the company. In its prior filing, the firm reported owning 25,911K shares , representing a decrease of 1.57%. The firm increased its portfolio allocation in VRTX by 13.46% over the last quarter.
Capital Research Global Investors holds 17,316K shares representing 6.83% ownership of the company. In its prior filing, the firm reported owning 16,553K shares , representing an increase of 4.41%. The firm increased its portfolio allocation in VRTX by 19.14% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 8,262K shares representing 3.26% ownership of the company. In its prior filing, the firm reported owning 8,112K shares , representing an increase of 1.82%. The firm decreased its portfolio allocation in VRTX by 16.55% over the last quarter.
VFINX – Vanguard 500 Index Fund Investor Shares holds 7,289K shares representing 2.87% ownership of the company. In its prior filing, the firm reported owning 7,134K shares , representing an increase of 2.12%. The firm decreased its portfolio allocation in VRTX by 16.65% over the last quarter.
Jpmorgan Chase holds 6,039K shares representing 2.38% ownership of the company. In its prior filing, the firm reported owning 6,435K shares , representing a decrease of 6.55%. The firm decreased its portfolio allocation in VRTX by 87.54% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.